Paclitaxel Expands TREM2+ Macrophages, Reducing Efficacy

Why It Matters

The discovery links a common chemotherapy to immune evasion, opening avenues for combination regimens that could improve response rates and patient survival.

Key Takeaways

• Paclitaxel increases TREM2+ macrophage population
• Expanded TREM2+ cells suppress anti‑tumor immunity
• Efficacy drop observed in preclinical models
• Combining TREM2 blockade restores paclitaxel response
• Suggests new combination therapy strategies

Pulse Analysis

Paclitaxel remains a cornerstone of solid‑tumor chemotherapy, yet resistance mechanisms continue to limit its long‑term success. Recent work has shifted focus from tumor‑intrinsic factors to the surrounding immune landscape, identifying TREM2‑expressing macrophages as key players that foster an immunosuppressive niche. By promoting the survival and expansion of these cells, paclitaxel inadvertently blunts the very immune activation needed for optimal tumor clearance, a paradox that reshapes our understanding of drug‑host interactions.

In mouse models of breast, lung, and ovarian cancers, investigators observed a 2‑ to 3‑fold rise in TREM2+ macrophages following standard paclitaxel dosing. These cells exhibited elevated expression of arginase‑1 and IL‑10, markers of an M2‑like phenotype that hinders cytotoxic T‑cell infiltration. Functional assays showed that depleting TREM2+ macrophages or applying a selective TREM2 antagonist restored tumor‑infiltrating lymphocyte activity and rescued paclitaxel‑induced tumor regression. The data provide compelling mechanistic evidence that TREM2‑mediated immunosuppression directly contributes to chemotherapy resistance.

Clinically, the study paves the way for rational combination strategies. Early‑phase trials could evaluate TREM2 inhibitors alongside paclitaxel, potentially lowering required chemotherapy doses while maintaining efficacy and reducing toxicity. Moreover, TREM2 expression may serve as a predictive biomarker to identify patients who would benefit most from such combos. As the oncology field embraces precision immuno‑oncology, integrating immune‑modulating agents with established chemotherapies could become a standard approach to overcome resistance and improve survival outcomes.